Journal of the American College of Surgeons
Volume 214, Issue 2 , Pages 164-173, February 2012

Reduction in Corticosteroids Is Associated with Better Health-Related Quality of Life after Liver Transplantation

Abstract presented at the 2010 Meeting of the International Hepato-Pancreato-Biliary Association, Buenos Aires, Argentina, April 2010.

  • Victor Zaydfudim, MD, MPH

      Affiliations

    • Department of Surgery and Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN
    • Corresponding Author InformationCorrespondence address: Victor Zaydfudim, MD, MPH, Division of Gastroenterologic and General Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905
  • ,
  • Irene D. Feurer, PhD

      Affiliations

    • Department of Surgery and Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN
    • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
  • ,
  • Matthew P. Landman, MD, MPH

      Affiliations

    • Department of Surgery and Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN
  • ,
  • Derek E. Moore, MD, MPH

      Affiliations

    • Department of Surgery and Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN
  • ,
  • J. Kelly Wright, MD, FACS

      Affiliations

    • Department of Surgery and Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN
  • ,
  • C. Wright Pinson, MBA, MD, FACS

      Affiliations

    • Department of Surgery and Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN

Received 14 July 2011; received in revised form 9 October 2011; accepted 10 October 2011. published online 02 December 2011.

Background

Corticosteroid use during post-transplant immunosuppression contributes to documented long-term complications in liver transplant recipients. However, the effects of steroids on post-transplant physical and mental health-related quality of life (HRQOL) have not been established. We aimed to test the association between steroid-based immunosuppression and post-transplant HRQOL in liver transplant recipients.

Study Design

We performed a retrospective analysis of prospective, longitudinal HRQOL measured using the Short Form 36 Health Survey physical and mental component summary scores, Beck Anxiety Inventory, and Center for Epidemiologic Studies Depression Scale. Steroid use (none, low [<10 mg/d], high [≥10 mg/d]) and temporally associated acute rejection (within previous 6 weeks, previous 7 to 12 weeks, and never or >12 weeks before HRQOL measurement) were determined at every post-transplant HRQOL data point. Linear mixed-effects models tested the effects of contemporaneous steroid use and dosing on post-transplant HRQOL.

Results

The sample included 186 adult liver transplant recipients (mean age 54 ± 8 years, 70% male) with pre- and at least 1 post-transplant HRQOL data point. Individual follow-up post-transplant averaged 21 ± 18 months (range 1 to 74 months). After controlling for pre-transplant HRQOL, time post-transplant, pre-transplant diagnosis group, and temporally associated episodes of rejection, post-transplant high-dose steroid use (≥10 mg/d) was associated with lower physical component summary (p < 0.001) and mental component summary (p = 0.049) scores and increased Beck Anxiety Inventory (p = 0.015) scores. Low-dose steroid use (<10 mg/d) was not associated with post-transplant HRQOL in any model (all p ≥ 0.28).

Conclusions

High-dose steroid use for post-transplant immunosuppression in liver transplant recipients was associated with reduced physical and mental HRQOL, and increased symptoms of anxiety. There was an association between better HRQOL and steroid reduction to <10 mg/d in liver transplant recipients during a broad follow-up period.

Abbreviations and Acronyms:  BAI, Beck Anxiety Inventory, CES-D, Center for Epidemiologic Studies Depression Scale, HCV, hepatitis C virus, HRQOL, health-related quality of life, MCS, mental component summary, PCS, physical component summary, SF-36, Short Form 36 Health Survey

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Disclosure Information: Nothing to disclose.

 This study was supported in part by the National Research Service Award T32 HS 013833 (V.Z.) from the Agency for Healthcare Research and Quality, US Department of Health and Human Services, and an educational award from the Novartis Corporation.

PII: S1072-7515(11)01157-4

doi:10.1016/j.jamcollsurg.2011.10.006

Journal of the American College of Surgeons
Volume 214, Issue 2 , Pages 164-173, February 2012